TY - JOUR
T1 - A comparison of early versus delayed elective electrical cardioversion for recurrent episodes of persistent atrial fibrillation
T2 - A multi-center study
AU - Voskoboinik, Aleksandr
AU - Kalman, Elana
AU - Plunkett, George
AU - Knott, Jonathan
AU - Moskovitch, Jeremy
AU - Sanders, Prashanthan
AU - Kistler, Peter M.
AU - Kalman, Jonathan M.
N1 - Funding Information:
Dr. Sanders reports having served on the advisory board of Biosense-Webster, Boston Scientific, CathRx, Medtronic, and St Jude Medical. Dr. Sanders reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Biosense-Webster, Medtronic, Boston-Scientific, Pfizer and St Jude Medical. Dr. Sanders reports that the University of Adelaide has received on his behalf research funding from Medtronic, St Jude Medical, Boston Scientific, Biotronik and Liva Nova. All other authors have no disclosures.
Funding Information:
Dr. Voskoboinik is supported by co-funded NHMRC/NHF post-graduate scholarships & Baker Institute Bright Sparks scholarships. Drs Sanders and Kalman are supported by a NHMRC practitioner fellowship. Dr. Sanders is supported by the National Heart Foundation of Australia (NHF).
Publisher Copyright:
© 2018
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Background: Due to barriers to accessing timely elective electrical cardioversion (CV) for persistent AF (PeAF), we adopted a policy of instructing patients to present directly to the Emergency Department (ED) for CV. Objective: We compare a strategy of Emergency CV (ED-CV) versus Elective CV (EL-CV) for treatment of symptomatic PeAF. Methods: Between 2014 and 7, we evaluated 150 patients undergoing CV for PeAF. ED-CV patients were provided an AF action plan for recurrent symptoms and advised to present to ED within 36 h. EL-CV patients followed standard care, including cardiologist referral and placement on an elective hospital waiting list. Follow-up was 12 months. Results: We included 75 consecutive ED-CV patients and 75 consecutive EL-CV patients. ED-CV patients had a significantly shorter median AF duration prior to CV (1 day vs 3 months; p < 0.01) and less overall AF-related symptoms at 12 months (modified EHRA symptom score ≥ 2a in 44% vs 72%; p = 0.005). Time to next AF recurrence was longer in the ED-CV group (295 ± 15 vs 245 ± 15 days; logrank p = 0.001), as was time to AF ablation referral (314 ± 13 vs 276 ± 15 days; logrank p = 0.01). Baseline LA area was similar (ED-CV 27 ± 4 cm 2 vs EL-CV 28 ± 11 cm 2 ; p = 0.67), however EL-CV had larger atria at follow-up (31 ± 8 vs 26 ± 6 cm 2 ; p = 0.01). There were no complications in either group. Conclusion: ED-CV is an acceptable strategy for symptomatic PeAF. In addition to reduced time spent in AF and improved symptom scores, this strategy may also slow progression of atrial substrate & delay onset of next AF episode.
AB - Background: Due to barriers to accessing timely elective electrical cardioversion (CV) for persistent AF (PeAF), we adopted a policy of instructing patients to present directly to the Emergency Department (ED) for CV. Objective: We compare a strategy of Emergency CV (ED-CV) versus Elective CV (EL-CV) for treatment of symptomatic PeAF. Methods: Between 2014 and 7, we evaluated 150 patients undergoing CV for PeAF. ED-CV patients were provided an AF action plan for recurrent symptoms and advised to present to ED within 36 h. EL-CV patients followed standard care, including cardiologist referral and placement on an elective hospital waiting list. Follow-up was 12 months. Results: We included 75 consecutive ED-CV patients and 75 consecutive EL-CV patients. ED-CV patients had a significantly shorter median AF duration prior to CV (1 day vs 3 months; p < 0.01) and less overall AF-related symptoms at 12 months (modified EHRA symptom score ≥ 2a in 44% vs 72%; p = 0.005). Time to next AF recurrence was longer in the ED-CV group (295 ± 15 vs 245 ± 15 days; logrank p = 0.001), as was time to AF ablation referral (314 ± 13 vs 276 ± 15 days; logrank p = 0.01). Baseline LA area was similar (ED-CV 27 ± 4 cm 2 vs EL-CV 28 ± 11 cm 2 ; p = 0.67), however EL-CV had larger atria at follow-up (31 ± 8 vs 26 ± 6 cm 2 ; p = 0.01). There were no complications in either group. Conclusion: ED-CV is an acceptable strategy for symptomatic PeAF. In addition to reduced time spent in AF and improved symptom scores, this strategy may also slow progression of atrial substrate & delay onset of next AF episode.
KW - Atrial fibrillation
KW - Atrial remodelling
KW - Electrical cardioversion
KW - Left atrium
UR - http://www.scopus.com/inward/record.url?scp=85055481738&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2018.10.068
DO - 10.1016/j.ijcard.2018.10.068
M3 - Article
C2 - 30917880
AN - SCOPUS:85055481738
SN - 0167-5273
VL - 284
SP - 33
EP - 37
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -